Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHughes, T.en
dc.contributor.authorHochhaus, A.en
dc.contributor.authorBranford, S.en
dc.contributor.authorMuller, M.en
dc.contributor.authorKaeda, J.en
dc.contributor.authorForoni, L.en
dc.contributor.authorDruker, B.en
dc.contributor.authorGuilhot, F.en
dc.contributor.authorLarson, R.en
dc.contributor.authorO'Brien, S.en
dc.contributor.authorRudoltz, M.en
dc.contributor.authorMone, M.en
dc.contributor.authorWehrle, E.en
dc.contributor.authorModur, V.en
dc.contributor.authorGoldman, J.en
dc.contributor.authorRadich, J.en
dc.identifier.citationBlood, 2010; 116(19):3758-3765en
dc.description.abstractThis study examines the prognostic significance of early molecular response using an expanded dataset in chronic myeloid leukemia patients enrolled in the International Randomized Study of Interferon and STI571 (IRIS). Serial molecular studies demonstrate decreases in BCR-ABL transcripts over time. Analyses of event-free survival (EFS) and time to progression to accelerated phase/blast crisis (AP/BC) at 7 years were based on molecular responses using the international scale (IS) at 6-, 12-, and 18-month landmarks. Patients with BCR-ABL transcripts > 10% at 6 months and > 1% at 12 months had inferior EFS and higher rate of progression to AP/BC compared with all other molecular response groups. Conversely, patients who achieved major molecular response [MMR: BCR-ABL (IS) ≤ 0.1%] by 18 months enjoyed remarkably durable responses, with no progression to AP/BC and 95% EFS at 7 years. The probability of loss of complete cytogenetic response by 7 years was only 3% for patients in MMR at 18 months versus 26% for patients with complete cytogenetic response but not MMR (P < .001). This study shows a strong association between the degree to which BCR-ABL transcript numbers are reduced by therapy and long-term clinical outcome, supporting the use of time-dependent molecular measures to determine optimal response to therapy. This study is registered at as NCT00006343.en
dc.description.statementofresponsibilityTimothy P. Hughes, Andreas Hochhaus, Susan Branford, Martin C. Müller, Jaspal S. Kaeda, Letizia Foroni, Brian J. Druker, François Guilhot, Richard A. Larson, Stephen G. O'Brien, Marc S. Rudoltz, Manisha Mone, Elisabeth Wehrle, Vijay Modur, John M. Goldman, Jerald P. Radich and on behalf of the IRIS investigatorsen
dc.publisherAmer Soc Hematologyen
dc.rights© 2010 by The American Society of Hematologyen
dc.subjectIRIS investigators; Humans; Benzamides; Piperazines; Pyrimidines; Interferons; Antineoplastic Agents; Prognosis; Disease-Free Survival; Treatment Outcome; Remission Induction; Genes, abl; Time Factors; Adolescent; Adult; Aged; Middle Aged; Female; Male; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Young Adult; Imatinib Mesylateen
dc.titleLong-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)en
dc.typeJournal articleen
pubs.library.collectionMedicine publicationsen
dc.identifier.orcidHughes, T. [0000-0002-0910-3730]en
dc.identifier.orcidBranford, S. [0000-0002-1964-3626]en
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.